Albany, NY — 01/16/2018 — The monocyte activation test is a type of pyrogen test. Pyrogens are substances that cause fever after administering injection. Increase in body ache and body temperature are harmful reactions caused due to injection of in the body. In monocyte activation test, Human blood cells are used to test a fever reaction that mimics the human immune reaction. Monocyte activation test measures cytokine released from monocytes when the human blood is exposed to a test substance. The quantity of cytokines released in the activation is done by the enzyme-linked immunesorbent assay (ELISA).
The monocyte activation test serves as the replacement for the rabbit pyrogen test and can be used to test parenteral drugs for non-endotoxin contaminations and endotoxin. Monocyte activation test is both robust and highly sensitivity. The monocyte activation test kit includes all the required consumables to perform the monocyte activation test that helps increase the convenience to perform. In addition to the kit, manufacturing companies also provide consulting services and technical support in setting up the monocyte activation test. Monocyte activation test is the preferred test option of the European pharmacopoeia, owing to the monocyte activation test does not use animals. Increasing production of cosmetic products supports the expansion of The Monocyte Activation Test Market, owing to the cosmetic products need to be tested for pyrogens. Increasing inclination toward animal-free detection tests, rising government initiatives to prevent diseases in order to curb health care costs, and increase in pharmaceutical outsourcing boosts the demand for monocyte activation test. However, high entry barrier for new market entrants and presence of small players are some factors restraining the global monocyte activation test market.
Globally, increasing number of biotechnology and pharmaceutical companies and rising health care awareness is shifting focus of patients toward the treatment of chronic and lifestyle diseases. These factors are driving the monocyte activation test market. Increasing research & development activities in the health care industry, rise in the number of new drug approvals, and growing incidences of chronic diseases are propelling the market. The global monocyte activation test market can be segmented based on application type, end-user, and region. In terms of application type, the market can be categorized into testing of air quality, lipid parenteral, dialysis liquids, toxic/immune-modulatory drugs, blood products, and medical devices. Based on end-user the market can be divided into pharmaceuticals industry, biotechnology industry, medical devices industry, and others.
Request to View Brochure of Report –
Geographically, the monocyte activation test market can be divided into Asia Pacific, Latin America, Europe, North America, and Middle East & Africa. North America held a dominant share of the market in 2016 due to growing health care awareness presence of key players in the region, and rise in technological advancements in research & development activities. Europe was the second dominant region in 2016 owing to companies initiatives, for instance, in September 2016, Merck joined DiViNe Project—a European consortium of six companies that work to address the challenges of development, manufacture, and delivery of vaccines. The market in Asia Pacific is anticipated to grow during the forecast period owing to increasing focus of key companies expanding their presence in countries in Asia to meet the growing market demand. Moreover, increasing government initiatives for health care awareness in the region also support the expansion of the market. Rising patient population diagnosed with chronic diseases the Asia also propel the market in the region. The market in Latin America and Middle East & Africa are anticipated to expand during the forecast period owing to increasing government initiatives.
Key players operating in the global monocyte activation test market include Microcoat Biotechnologie GmbH, Thermo Fisher Scientific, Inc., and Merck KGaA.
Pre-Book Full Report –
Powered by WPeMatico